EMA Authorised: Respreeza (human alpha1-proteinase inhibitor) — CSL Behring GmbH

View source ↗

Summary

The EMA authorised Respreeza (human alpha1-proteinase inhibitor) for alpha-1 antitrypsin deficiency–related lung disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• Respreeza (alpha-1 proteinase inhibitor (human))

Snippet

Status: Authorised. Therapeutic area: Genetic Diseases, Inborn;Lung Diseases. MAH: CSL Behring GmbH. Decision date: 26/03/2025